CoChat

Gut Microbiota Composition Is Related to AD Pathology

Open access
Verhaar, Barbara J. H., Hendriksen, Heleen M. A., de Leeuw, Francisca A., Doorduijn, Astrid S., van Leeuwenstijn, Mardou, Teunissen, Charlotte E., Barkhof, Frederik, Scheltens, Philip, Kraaij, Robert, van Duijn, Cornelia M., Nieuwdorp, Max, Muller, Majon, van der Flier, Wiesje M. · 2022 · Frontiers in Immunology
Cited by 224

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Introduction: Several studies have reported alterations in gut microbiota composition of Alzheimer’s disease (AD) patients. However, the observed differences are not consistent across studies. We aimed to investigate associations between gut microbiota composition and AD biomarkers using machine learning models in patients with AD dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD). Materials and Methods: We included 170 patients from the Amsterdam Dementia Cohort, comprising 33 with AD dementia (66 ± 8 years, 46%F, mini-mental state examination (MMSE) 21[19-24]), 21 with MCI (64 ± 8 years, 43%F, MMSE 27[25-29]) and 116 with SCD (62 ± 8 years, 44%F, MMSE 29[28-30]). Fecal samples were collected and gut microbiome composition was determined using 16S rRNA sequencing. Biomarkers of AD included cerebrospinal fluid (CSF) amyloid-beta 1-42 (amyloid) and phosphorylated tau (p-tau), and MRI visual scores (medial temporal atrophy, global cortical atrophy, white matter hyperintensities). Associations between gut microbiota composition and dichotomized AD biomarkers were assessed with machine learning classification models. The two models with the highest area under the curve (AUC) were selected for logistic regression, to assess associations between the 20 best predicting microbes and the outcome measures from these machine learning models while adjusting for age, sex, BMI, diabetes, medication use, and MMSE. Results: The machine learning prediction for amyloid and p-tau from microbiota composition performed best with AUCs of 0.64 and 0.63. Highest ranked microbes included several short chain fatty acid (SCFA)-producing species. Higher abundance of [Clostridium] leptum and lower abundance of [Eubacterium] ventriosum group spp., Lachnospiraceae spp., Marvinbryantia spp., Monoglobus spp., [Ruminococcus] torques group spp., Roseburia hominis, and Christensenellaceae R-7 spp., was associated with higher odds of amyloid positivity. We found associations between lower abundance of Lachnospiraceae spp., Lachnoclostridium spp., Roseburia hominis and Bilophila wadsworthia and higher odds of positive p-tau status. Conclusions: Gut microbiota composition was associated with amyloid and p-tau status. We extend on recent studies that observed associations between SCFA levels and AD CSF biomarkers by showing that lower abundances of SCFA-producing microbes were associated with higher odds of positive amyloid and p-tau status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2021.794519

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 41

  1. van Olst, 2021, Contribution of Gut Microbiota to Immunological Changes in Alzheimer’s Disease, Front Immunol, 12, 10.3389/fimmu.2021.683068 · DOI
  2. Saresella, 2020, Alterations in Circulating Fatty Acid Are Associated With Gut Microbiota Dysbiosis and Inflammation in Multiple Sclerosis, Front Immunol, 11, 10.3389/fimmu.2020.01390 · DOI · Paper page
  3. Moccia, 2020, Single-Arm, Non-Randomized, Time Series, Single-Subject Study of Fecal Microbiota Transplantation in Multiple Sclerosis, Front Neurol, 11, 10.3389/fneur.2020.00978 · DOI
  4. Scott, 2013, The Influence of Diet on the Gut Microbiota, Pharmacol Res, 69, 52, 10.1016/j.phrs.2012.10.020 · DOI · Paper page
  5. Deleu, 2021, Short Chain Fatty Acids and its Producing Organisms: An Overlooked Therapy for IBD, EBioMedicine, 66, 103293, 10.1016/j.ebiom.2021.103293 · DOI · Paper page
  6. Sun, 2019, Fecal Microbiota Transplantation Alleviated Alzheimer’s Disease-Like Pathogenesis in APP/PS1 Transgenic Mice, Transl Psychiatry, 9, 1, 10.1038/s41398-019-0525-3 · DOI · Paper page
  7. Kim, 2020, Transfer of a Healthy Microbiota Reduces Amyloid and Tau Pathology in an Alzheimer’s Disease Animal Model, Gut, 69, 10.1136/gutjnl-2018-317431 · DOI · Paper page
  8. Cox, 2019, Calorie Restriction Slows Age-Related Microbiota Changes in an Alzheimer’s Disease Model in Female Mice, Sci Rep, 9, 1, 10.1038/s41598-019-54187-x · DOI · Paper page
  9. Fernando, 2020, Sodium Butyrate Reduces Brain Amyloid-β Levels and Improves Cognitive Memory Performance in an Alzheimer’s Disease Transgenic Mouse Model at an Early Disease Stage, J Alzheimer’s Dis, 74, 10.3233/JAD-190120 · DOI · Paper page
  10. Mirzayi, 2021, Reporting Guidelines for Human Microbiome Research: The STORMS Checklist, Nat Med, 27, 10.1038/s41591-021-01552-x · DOI · Paper page
  11. van der Flier, 2014, Optimizing Patient Care and Research: The Amsterdam Dementia Cohort, J Alzheimer’s Dis, 41, 10.3233/JAD-132306 · DOI · Paper page
  12. van der Flier, 2018, Amsterdam Dementia Cohort: Performing Research to Optimize Care, J Alzheimer’s Dis, 62, 10.3233/JAD-170850 · DOI · Paper page
  13. Slot, 2018, Subjective Cognitive Impairment Cohort (SCIENCe): Study Design and First Results, Alzheimer’s Res Ther, 10, 1, 10.1186/s13195-018-0390-y · DOI · Paper page
  14. McKhann, 1984, Clinical Diagnosis of Alzheimer’s Disease, Neurology, 34, 10.1212/WNL.34.7.939 · DOI · Paper page
  15. Mulder, 2010, Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease, Clin Chem, 56, 10.1373/clinchem.2009.130518 · DOI · Paper page
  16. Tijms, 2018, Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1–42 Analysis Results, Clin Chem, 64, 10.1373/clinchem.2017.281055 · DOI · Paper page
  17. Willemse, 2018, Diagnostic Performance of Elecsys Immunoassays for Cerebrospinal Fluid Alzheimer’s Disease Biomarkers in a Nonacademic, Multicenter Memory Clinic Cohort: The ABIDE Project, Alzheimer’s Dement Diagn Assess Dis Monit, 10, 563, 10.1016/J.DADM.2018.08.006 · DOI · Paper page
  18. Scheltens, 1992, Atrophy of Medial Temporal Lobes on MRI in “Probable” Alzheimer’s Disease and Normal Ageing: Diagnostic Value and Neuropsychological Correlates, J Neurol Neurosurg Psychiatry, 55, 10.1136/jnnp.55.10.967 · DOI · Paper page
  19. Rhodius-Meester, 2017, MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities Across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis, Front Aging Neurosci, 9, 117, 10.3389/fnagi.2017.00117 · DOI · Paper page
  20. Pasquier, 1996, Inter-And Intraobserver Reproducibility of Cerebral Atrophy Assessment on Mri Scans With Hemispheric Infarcts, Eur Neurol, 36, 10.1159/000117270 · DOI · Paper page
  21. Fazekas, 1987, MR Signal Abnormalities at 1.5 T in Alzheimer’s Dementia and Normal Aging, Am J Roentgenol, 8, 421, 10.2214/ajr.149.2.351 · DOI · Paper page
  22. Wardlaw, 2013, Neuroimaging Standards for Research Into Small Vessel Disease and its Contribution to Ageing and Neurodegeneration, Lancet Neurol, 12, 10.1016/S1474-4422(13)70124-8 · DOI · Paper page
  23. Faith, 1992, Conservation Evaluation and Phylogenetic Diversity, Biol Conserv, 61, 1, 10.1016/0006-3207(92)91201-3 · DOI · Paper page
  24. Hill, 1973, Diversity and Evenness: A Unifying Notation and Its Consequences, Ecology, 54, 10.2307/1934352 · DOI · Paper page
  25. Wang, 2020, Comparative Study of Classifiers for Human Microbiome Data, Med Microecol, 4, 100013, 10.1016/j.medmic.2020.100013 · DOI
  26. Xaio, 2001, Effect of LPS on the Permeability of the Blood–Brain Barrier to Insulin, Brain Res, 896, 36, 10.1016/S0006-8993(00)03247-9 · DOI · Paper page
  27. Moissl-Eichinger, 2016, Bacteroides Fragilis Lipopolysaccharide and Inflammatory Signaling in Alzheimer’s Disease, Front Microbiol, 7, 10.3389/fmicb.2016.01544 · DOI · Paper page
  28. Wang, 2014, A Commensal Bacterial Product Elicits and Modulates Migratory Capacity of CD39+ CD4 T Regulatory Subsets in the Suppression of Neuroinflammation, Gut Microbes, 5, 10.4161/gmic29797 · doi:10.4161/gmic29797
  29. Venegas, 2019, Short Chain Fatty Acids (SCFAs) Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases, Front Immunol, 10, 277, 10.3389/fimmu.2019.00277 · DOI · Paper page
  30. Verberk, 2021, Serum Markers Glial Fibrillary Acidic Protein and Neurofilament Light for Prognosis and Monitoring in Cognitively Normal Older People: A Prospective Memory Clinic-Based Cohort Study, Lancet Heal Longev, 2, 10.1016/S2666-7568(20)30061-1 · DOI · Paper page
  31. Poehlman, 2000, Energy Expenditure, Energy Intake, and Weight Loss in Alzheimer Disease, Am J Clin Nutr, 71, 10.1093/ajcn/71.2.650s · DOI
  32. Doorduijn, 2020, Energy Intake and Expenditure in Patients With Alzheimer’s Disease and Mild Cognitive Impairment: The NUDAD Project, Alzheimer’s Res Ther, 12, 1, 10.1186/s13195-020-00687-2 · DOI
  33. Vieira, 2016, New Insights Into Therapeutic Strategies for Gut Microbiota Modulation in Inflammatory Diseases, Clin Transl Immunol, 5, e87, 10.1038/cti.2016.38 · DOI · Paper page
  34. Meijnikman, 2018, Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans, Endocr Rev, 39, 10.1210/er.2017-00192 · DOI · Paper page
  35. Groot, 2021, Faecal Microbiota Transplantation Halts Progression of Human New-Onset Type 1 Diabetes in a Randomised Controlled Trial, Gut, 70, 92, 10.1136/gutjnl-2020-322630 · DOI · Paper page
  36. Hartstra, 2020, Infusion of Donor Feces Affects the Gut–Brain Axis in Humans With Metabolic Syndrome, Mol Metab, 42, 101076, 10.1016/j.molmet.2020.101076 · DOI · Paper page
  37. Chen, 2021, Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank, Front Cell Infect Microbiol, 10.3389/fcimb.2021.622949 · DOI
  38. Zhu, 2021, Probiotics for Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis, Foods, 10, 1672, 10.3390/foods10071672 · DOI · Paper page
  39. Andrade, 2020, Commensal Obligate Anaerobic Bacteria and Health: Production, Storage, and Delivery Strategies, Front Bioeng Biotechnol, 8, 1, 10.3389/fbioe.2020.00550 · DOI
  40. Wijdeveld, 2020, The Interaction Between Microbiome and Host Central Nervous System: The Gut-Brain Axis as a Potential New Therapeutic Target in the Treatment of Obesity and Cardiometabolic Disease, Expert Opin Ther Targets, 24, 10.1080/14728222.2020.1761958 · DOI
  41. Bouter, 2018, Differential Metabolic Effects of Oral Butyrate Treatment in Lean Versus Metabolic Syndrome Subjects Article, Clin Transl Gastroenterol, 9, 155, 10.1038/s41424-018-0025-4 · DOI · Paper page

Cited by

See all 224

Metadata

Authors
Verhaar, B. J. H., Hendriksen, H. M. A., de Leeuw, F. A., Doorduijn, A. S., van Leeuwenstijn, M., Teunissen, C. E., Barkhof, F., Scheltens, P., Kraaij, R., van Duijn, C. M., Nieuwdorp, M., Muller, M., & van der Flier, W. M.
Venue
Frontiers in Immunology
Published
2022-01-31
Volume
12
Pages
794519-794519
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4210640577
Cited by
224
References
23
FWCI
13.26
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut Microbiota Composition Is Related to AD Pathology. https://app.cochat.ai/papers/10.3389/fimmu.2021.794519
The paper
Verhaar, B. J. H., Hendriksen, H. M. A., de Leeuw, F. A., Doorduijn, A. S., van Leeuwenstijn, M., Teunissen, C. E., Barkhof, F., Scheltens, P., Kraaij, R., van Duijn, C. M., Nieuwdorp, M., Muller, M., & van der Flier, W. M. (2022). Gut Microbiota Composition Is Related to AD Pathology. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.794519

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.